Clinical Trial Update: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, pharmacodynamics, and pharmacokinetics of SHP141 in patients with cutaneous T-cell lymphoma (CTCL); results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• SHP141 (SHP141)

Snippet

Sponsor: TetraLogic Pharmaceuticals | Conditions: Lymphoma, T-Cell, Cutaneous | Phase 1 | Status: COMPLETED | Results posted: 2016-03-24